openPR Logo
Press release

Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics - Pipeline Analysis | Zymenex, BioXcel Corporation

Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics -

Globoid cell leukodystrophy, also known as Krabbe disease, is a genetic disorder which is characterized by decreased production of galactocerebrosidase. The symptoms observed during Krabbe disease are fever, vomiting, loss of head control, irritability and excessive crying, seizures, poor coordination of movement or stiffness, muscle spasms, changes in muscle tone, deterioration of motor function, difficulty walking and muscle weakness.

Download the sample report @ https://www.pharmaproff.com/request-sample/1133

There is no cure for Krabbe disease, however, hematopoietic stem cell transplant (HSCT) has demonstrated some positive effects on the disease. Moreover, patient’s quality of life can be improved by anticonvulsant medication to stop seizures, muscle relaxer drugs, physical therapy to help slow deterioration of muscles and occupational therapy.

Get the detailed analysis @ https://www.pharmaproff.com/report/globoid-cell-leukodystrophy-therapeutics-pipeline-analysis

MediciNova Inc. is developing MN-166 (ibudilast) as a novel, orally bioavailable small molecule compound which exerts its effects through several mechanisms to produce its anti-fibrotic and anti-inflammatory activity for the treatment of Krabbe disease. BioXcel Corporation, and Zymenex A/S are some other key players involved in the development of therapeutics for Krabbe disease.

Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1133

• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Globoid Cell Leukodystrophy (Krabbe Disease) Therapeutics - Pipeline Analysis | Zymenex, BioXcel Corporation here

News-ID: 1727287 • Views:

More Releases for Krabbe

Krabbe Disease Drugs Market Global Strategies and Insight driven transformation …
Krabbe Disease Drugs Market research report is a professional and an in-depth study available on the market size, share, growth, trends, in addition to industry evaluation. Krabbe Disease Drugs Market report provides a thorough analysis and competitive analysis by region and added main information like a manufacturing process, raw material and equipment suppliers, various manufacturing associated costs, revenue, historical and futuristic cost, demand and supply data. Moreover, the study presents a
Krabbe Disease Treatment Market - Global Industry Trends,Size, Applications and …
Krabbe disease is a rare inherited genetic disorder that affects the nervous system. It is usually caused by the deficiency of the galactosylceramidase (GLC) enzyme. The disease is inherited in an autosomal recessive pattern. global krabbe disease treatment market to grow at a CAGR of 7.24% during the period 2018-2022. Get Sample@ https://www.researchbeam.com/global-krabbe-disease-treatment-2018-2022-market/request-sample Covered in this report The report covers the present scenario and the growth prospects of the global krabbe disease
Krabbe Disease Treatment Market to Observe Strong Development by 2025
Krabbe disease treatment is a rare autosomal recessive lysosomal related disorder affecting the white matter of the peripheral and central nervous system. It is a genetic disorder, which is passed down one generation to another in families. It is also called globoid cell leukodystrophy disease. Persons suffering from Krabbe disease treatment are unable to produce sufficient amount of galactosylceramidase, which is essential for myelin production and breaks down several important
Krabbe Disease Treatment Market Flourishes Key Players Share, Revenue, Demand an …
The Global Krabbe Disease Treatment Market report explores the key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market. The Krabbe Disease Treatment Market has been segmented on the basis of types of treatments which comprises of anticonvulsant medication, physical therapy, muscle relaxer drugs, bone marrow transplantation and others. On the basis of end users the market is
Global Clinical Trials Review for Globoid Cell Leukodystrophy (Krabbe Disease), …
"The Report Globoid Cell Leukodystrophy (Krabbe Disease) Global Clinical Trials Review, H2, 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" ​Globoid Cell Leukodystrophy (Krabbe Disease) Global Clinical Trials Review, H2, 2017 Summary GlobalDatas clinical trial report, Globoid Cell Leukodystrophy (Krabbe Disease) Global Clinical Trials Review, H2, 2017" provides an overview of Globoid Cell Leukodystrophy (Krabbe Disease) clinical trials scenario. Get Sample copy of this
Krabbe Disease Treatment Market 2022 – GlaxoSmithKline, Shire, Novartis AG, Ab …
Market Research Future adds new report of “Krabbe Disease Treatment Market Research Report- Forecast to 2022” it contains Company information, geographical data and Table of Content Competitive Analysis: Some of the key players in this market are: • Abbott Laboratories • Teva Pharmaceutical Industries Ltd. • GlaxoSmithKline • Johnson & Johnson • Novartis AG • Pfizer • Sanofi-Aventis SA • Shire • UCB Pharmaceuticals Get a Sample Report @ https://www.marketresearchfuture.com/sample_request/1833 Market Segments: Krabbe Disease treatment market has been segmented • On the basis of Types Of Treatments which comprises of anticonvulsant